{"classes":[{"categories":[{"measurements":[{"comment":"Median and inter-quartile range was not reached.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"1.46","upperLimit":"16.10","value":"5.85"},{"comment":"No event occurred for single participant hence Median and Inter-quartile range could not be calculated.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"OS is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. Median and inter-quartile range (first quartile and third quartile) of overall survival are presented.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG000","title":"Part 2: GSK525762 60 mg QD CTCL"},{"description":"Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Part 2: GSK525762 75 mg QD MDS"},{"description":"Participants CTCL were administered once daily oral dose of 80 mg GSK525762","id":"OG002","title":"Part 2: GSK525762 80 mg QD CTCL"}],"paramType":"MEDIAN","populationDescription":"All Treated Population.","reportingStatus":"POSTED","timeFrame":"Up to 36.4 weeks","title":"Part 2: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}